Tovetumab (Synonyms: MEDI-575) |
| رقم الكتالوجGC66385 |
Tovetumab (MEDI-575) هو مضاد لـ PDGFRα ؛ الأجسام المضادة أحادية النسيلة التي تمنع بشكل انتقائي PDGFRα ؛ نقل الإشارة. يمكن استخدام توفيتوماب في البحث عن ورم أرومي دبقي وسرطان الرئة ذو الخلايا غير الصغيرة (NSCLC).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1243266-04-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC)[1][2].
Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab)[1].
Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells[2].
Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs) [2].
Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys[1].
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts[2].
| Animal Model: | Cynomolgus monkey[1] |
| Dosage: | 0.6, 6.0, and 60 mg/kg |
| Administration: | Intravenous injection (i.v.) |
| Result: | Induced > 100- fold increases in circulating concentrations of PDGF-AA. |
| Animal Model: | U118 glioma xenografts (CB17 SCID)[2] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), twice per week. |
| Result: | Produced 101% inhibition of tumor growth. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *